ECCMID 26th (2016)

Drupal spam blocked by CleanTalk.
Title Content type
Is fluconazole resistance (FLU-R) in Cryptococcus neoformans predictive of clinical outcome? (click for details)
Evaluation of the Sensititre YeastOne colorimetric antifungal panel for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin, adopting the new CLSI clinical breakpoints and epidemiological cutoff values (click for details)
EDTA inhibits Rhizopus oryzae (Rhizopus arrhizus) growth in vitro in blood of diabetic and non-diabetic individuals - is it an option for combined therapy with antifungal agents in the future? (click for details)
Factors correlated to the length of antifungal therapy in a cohort of patients with candidaemia (click for details)
Differences in cytokine levels in diabetic versus non-diabetic mice challenged with Candida albicans and treated with liposomal amphotericin B (click for details)
Subinhibitory concentrations of micafungin exert species-dependent differential effects on Candida and modulate the antifungal activity of human neutrophils against mature biofilms (click for details)
Economic analysis of diagnostic-driven versus empirical strategies for the treatment of immunocompromised patients with suspected fungal infections in Egypt (click for details)
Anti-biofilm properties of Peganum harmala against Candida albicans (click for details)
Once-weekly dosing requires a proportionally higher dosage of micafungin for treatment of experimental disseminated candidiasis caused by Candida glabrata in persistently neutropenic rabbits (click for details)
Determination of a EUCAST PK/PD breakpoint for voriconazole and Candida glabrata (click for details)


Subscribe to ECCMID 26th (2016)